NCT03201965 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 193
- group Id
- BG002
- value
- 195
- group Id
- BG003
- value
- 416
- units
- Participants
- groups
- description
- Participants received the combination therapy during Run-in phase starting with 20 milligrams (mg) dexamethasone as premedication followed by daratumumab 1800 mg on Day 1 Cycle 1, then cyclophosphamide 300 milligram per meter square (mg/m\^2) orally or intravenous (IV) maximum weekly dose 500 mg, followed by bortezomib 1.3 mg/m\^2 subcutaneous (SC) injection once every week and dexamethasone remaining 20 mg post daratumumab dosing for up to 1 cycle (28 Days) to assess the safety before randomizing participants in CyBorD or daratumumab plus CyBorD arms. However, participants also continued daratumumab plus CyBorD for up to 6 cycles and then daratumumab monotherapy for up to 24 months from the start of treatment. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG000
- title
- Run-In: Daratumumab Plus CyBorD
- description
- Participants received dexamethasone (40 mg weekly dose)starting from cycle 1 day1 in every 28-day cycle followed by cyclophosphamide 300 mg/m\^2 orally or IV maximum weekly dose 500 mg and then bortezomib 1.3 mg/m\^2 SC injection once weekly up to 7.33 months. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG001
- title
- CyBorD
- description
- Participants received combination therapy for six cycles of 28 days each, daratumumab 1800 mg SC weekly starting from cycles 1 day 1 and cycle 2, every 2 weeks in cycles 3 through 6, dexamethasone 40 mg weekly (on days of daratumumab dosing, dexamethasone was split, 20 mg as premedication and 20 mg as post daratumumab dosing), cyclophosphamide 300 mg/m\^2 orally or IV maximum weekly dose 500 mg, bortezomib 1.3 mg/m\^2 SC injection once weekly. After 6 cycles, participants continued to receive daratumumab SC monotherapy until disease progression, start of subsequent therapy or up to 26.71 months from the first dose of study treatment. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG002
- title
- Daratumumab Plus CyBorD
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.2
- value
- 64.8
- group Id
- BG001
- spread
- 9.66
- value
- 64
- group Id
- BG002
- spread
- 10.16
- value
- 62.2
- group Id
- BG003
- spread
- 10.03
- value
- 63.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 87
- group Id
- BG003
- value
- 174
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 108
- group Id
- BG003
- value
- 241
- title
- Male
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Undifferentiated Sex
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex/Gender, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 179
- group Id
- BG003
- value
- 381
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 12
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 64
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 15
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 143
- group Id
- BG002
- value
- 151
- group Id
- BG003
- value
- 319
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 27
- title
- AUSTRALIA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 11
- title
- BRAZIL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 19
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 12
- title
- CHINA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- DENMARK
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 38
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 19
- title
- GERMANY
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 27
- title
- GREECE
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- title
- HUNGARY
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 11
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 9
- title
- ITALY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 62
- group Id
- BG003
- value
- 141
- title
- <=65 kg
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 96
- group Id
- BG003
- value
- 182
- title
- >65 to 85 kg
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 37
- group Id
- BG003
- value
- 93
- title
- >85 kg
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Weight group in Kilograms (Kg)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 137
- group Id
- BG002
- value
- 140
- group Id
- BG003
- value
- 294
- title
- Baseline Organ Involvement: Heart
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 115
- group Id
- BG003
- value
- 248
- title
- Baseline Organ Involvement: Kidney
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 35
- title
- Baseline Organ Involvement: Liver
- description
- Organ involvement assessment: biopsy. Heart: echo: mean wall thickness greater than (\>) 12 millimeter, no other cardiac cause; kidney: 24- hour urine protein \>0.5 gram per day, predominantly albumin; liver: total liver span \>15 centimeter in absence of heart failure or alkaline phosphatase \>1.5 times institutional upper limit of normal.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Baseline Major Organ Involvement
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.881
- value
- 2.0
- group Id
- BG001
- spread
- 1.03
- value
- 2.0
- group Id
- BG002
- spread
- 0.97
- value
- 2.0
- group Id
- BG003
- spread
- 0.99
- value
- 2.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Number of Organs Involved
- unit Of Measure
- organs
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 66
- group Id
- BG003
- value
- 143
- title
- 1 Organ
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 76
- group Id
- BG003
- value
- 166
- title
- 2 Organs
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 107
- title
- >=3 Organ
- description
- Number of participants whose 1 organ, 2 organs, 3 or more than 3 organs involved at baseline was reported. Organs like heart, kidney, and liver were considered.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Organs Involved
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 96
- title
- Class I
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 76
- group Id
- BG003
- value
- 172
- title
- Class II
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 70
- group Id
- BG003
- value
- 139
- title
- Class IIIa
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 9
- title
- Class IIIb
- description
- Cardiac stage is derived based on the combination of NT-proBNP (N-terminal pro b-type natriuretic peptide) and hs-cTnT (high sensitivity cardiac troponin T). Risk factor includes NT-proBNP \>332 nanogram per liter (ng/L) and Hs-cTnT \>54 ng/L. Stage I includes no markers above the cutoff, stage 2 includes one marker above the cutoff, stage 3a includes both markers above the cutoff, and stage 3b includes NT-proBNP \>8500 ng/L and hs-cTnT \>54 ng/L.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Cardiac Stage Based on Mayo Clinic Cardiac Staging System
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 101
- group Id
- BG003
- value
- 212
- title
- Class I
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 77
- group Id
- BG003
- value
- 176
- title
- Class II
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 28
- title
- Class IIIA
- description
- The NYHA classification: Class I- No symptoms and no limitation in ordinary physical activity, example, shortness of breath when walking, climbing stairs; class II- mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; class IIIA- marked limitation in activity due to symptoms, even during less than ordinary activity, example, walking short distances (20-100 meter).Comfortable only at rest.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- New York Heart Association (NYHA) Class
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 193
- group Id
- BG002
- value
- 195
- group Id
- BG003
- value
- 416
- units
- Participants
- groups
- description
- Participants received the combination therapy during Run-in phase starting with 20 milligrams (mg) dexamethasone as premedication followed by daratumumab 1800 mg on Day 1 Cycle 1, then cyclophosphamide 300 milligram per meter square (mg/m\^2) orally or intravenous (IV) maximum weekly dose 500 mg, followed by bortezomib 1.3 mg/m\^2 subcutaneous (SC) injection once every week and dexamethasone remaining 20 mg post daratumumab dosing for up to 1 cycle (28 Days) to assess the safety before randomizing participants in CyBorD or daratumumab plus CyBorD arms. However, participants also continued daratumumab plus CyBorD for up to 6 cycles and then daratumumab monotherapy for up to 24 months from the start of treatment. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG000
- title
- Run-In: Daratumumab Plus CyBorD
- description
- Participants received dexamethasone (40 mg weekly dose)starting from cycle 1 day1 in every 28-day cycle followed by cyclophosphamide 300 mg/m\^2 orally or IV maximum weekly dose 500 mg and then bortezomib 1.3 mg/m\^2 SC injection once weekly up to 7.33 months. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG001
- title
- CyBorD
- description
- Participants received combination therapy for six cycles of 28 days each, daratumumab 1800 mg SC weekly starting from cycles 1 day 1 and cycle 2, every 2 weeks in cycles 3 through 6, dexamethasone 40 mg weekly (on days of daratumumab dosing, dexamethasone was split, 20 mg as premedication and 20 mg as post daratumumab dosing), cyclophosphamide 300 mg/m\^2 orally or IV maximum weekly dose 500 mg, bortezomib 1.3 mg/m\^2 SC injection once weekly. After 6 cycles, participants continued to receive daratumumab SC monotherapy until disease progression, start of subsequent therapy or up to 26.71 months from the first dose of study treatment. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).
- id
- BG002
- title
- Daratumumab Plus CyBorD
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.2
- value
- 64.8
- group Id
- BG001
- spread
- 9.66
- value
- 64
- group Id
- BG002
- spread
- 10.16
- value
- 62.2
- group Id
- BG003
- spread
- 10.03
- value
- 63.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 87
- group Id
- BG003
- value
- 174
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 108
- group Id
- BG003
- value
- 241
- title
- Male
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Undifferentiated Sex
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex/Gender, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 179
- group Id
- BG003
- value
- 381
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 12
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 64
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 15
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 143
- group Id
- BG002
- value
- 151
- group Id
- BG003
- value
- 319
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 27
- title
- AUSTRALIA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 11
- title
- BRAZIL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 19
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 12
- title
- CHINA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- DENMARK
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 38
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 19
- title
- GERMANY
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 27
- title
- GREECE
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- title
- HUNGARY
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 11
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 9
- title
- ITALY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 62
- group Id
- BG003
- value
- 141
- title
- <=65 kg
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 96
- group Id
- BG003
- value
- 182
- title
- >65 to 85 kg
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 37
- group Id
- BG003
- value
- 93
- title
- >85 kg
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Weight group in Kilograms (Kg)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 137
- group Id
- BG002
- value
- 140
- group Id
- BG003
- value
- 294
- title
- Baseline Organ Involvement: Heart
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 115
- group Id
- BG003
- value
- 248
- title
- Baseline Organ Involvement: Kidney
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 35
- title
- Baseline Organ Involvement: Liver
- description
- Organ involvement assessment: biopsy. Heart: echo: mean wall thickness greater than (\>) 12 millimeter, no other cardiac cause; kidney: 24- hour urine protein \>0.5 gram per day, predominantly albumin; liver: total liver span \>15 centimeter in absence of heart failure or alkaline phosphatase \>1.5 times institutional upper limit of normal.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Baseline Major Organ Involvement
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.881
- value
- 2.0
- group Id
- BG001
- spread
- 1.03
- value
- 2.0
- group Id
- BG002
- spread
- 0.97
- value
- 2.0
- group Id
- BG003
- spread
- 0.99
- value
- 2.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Number of Organs Involved
- unit Of Measure
- organs
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 66
- group Id
- BG003
- value
- 143
- title
- 1 Organ
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 76
- group Id
- BG003
- value
- 166
- title
- 2 Organs
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 107
- title
- >=3 Organ
- description
- Number of participants whose 1 organ, 2 organs, 3 or more than 3 organs involved at baseline was reported. Organs like heart, kidney, and liver were considered.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Organs Involved
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 96
- title
- Class I
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 76
- group Id
- BG003
- value
- 172
- title
- Class II
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 70
- group Id
- BG003
- value
- 139
- title
- Class IIIa
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 9
- title
- Class IIIb
- description
- Cardiac stage is derived based on the combination of NT-proBNP (N-terminal pro b-type natriuretic peptide) and hs-cTnT (high sensitivity cardiac troponin T). Risk factor includes NT-proBNP \>332 nanogram per liter (ng/L) and Hs-cTnT \>54 ng/L. Stage I includes no markers above the cutoff, stage 2 includes one marker above the cutoff, stage 3a includes both markers above the cutoff, and stage 3b includes NT-proBNP \>8500 ng/L and hs-cTnT \>54 ng/L.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Cardiac Stage Based on Mayo Clinic Cardiac Staging System
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 101
- group Id
- BG003
- value
- 212
- title
- Class I
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 77
- group Id
- BG003
- value
- 176
- title
- Class II
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 28
- title
- Class IIIA
- description
- The NYHA classification: Class I- No symptoms and no limitation in ordinary physical activity, example, shortness of breath when walking, climbing stairs; class II- mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; class IIIA- marked limitation in activity due to symptoms, even during less than ordinary activity, example, walking short distances (20-100 meter).Comfortable only at rest.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- New York Heart Association (NYHA) Class
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle